Treatment with interferon-beta does not induce anti-nuclear and anti-neuronal serum autoantibodies in multiple sclerosis patients

Journal of Neuroimmunology

Volumn 255, Issue 1-2, 2013, Pages 102-104

  Comabella, M ^a   Rentzsch, K ^b   Rio J ^a   Bustamante, M F ^a   Borowski, K ^b   Stoecker, W ^b   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Institute of Experimental Immunology   (Germany)

Author keywords

Humoral immunity, autoantibodies; Interferon beta; Multiple sclerosis; Response to treatment

Indexed keywords

AUTOANTIBODY; BETA INTERFERON; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEURONS; YOUNG ADULT;

EID: 84872651094     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.016     Document Type: Article

References (10)

1. Comabella M., Lunemann J.D., Rio J., Sanchez A., Lopez C., Julià E., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
2. Covini G., Carcamo W.C., Bredi E., von Mühlen C.A., Colombo M., Chan E.K. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir. Ther. 2001, (Epub ahead of print 1 Dec 2011). 10.3851/IMP1993.
3. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kümpfel T., Pellkofer H., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
4. Hedegaard C.J., Sellebjerg F., Krakauer M., Hesse D., Bendtzen K., Nielsen C.H. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult. Scler. 2011, 17:567-577.
5. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
6. Polman C.H., Kappos L., Dahlke F., Graf R., Beckmann K., Bogumil T., et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005, 64:996-1000.
7. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
8. Río J., Nos C., Tintoré M., Borrás C., Galán I., Comabella M., et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol. 2002, 52:400-406.
9. Río J., Nos C., Tintoré M., Tellez N., Galan I., Pelayo R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 2006, 59:344-352.
10. Thorn M., Lewis R.H., Mumbey-Wafula A., Kantrowitz S., Spatz L.A. BAFF overexpression promotes antidsDNA B-cell maturation and antibody secretion. Cell. Immunol. 2010, 261:9-22.